Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
19 studies found for:    Open Studies | copd | United States, North Carolina
Show Display Options
Rank Status Study
1 Recruiting Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients.
Condition: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Drug: QVA149;   Drug: Umeclidinium/vilanterol;   Drug: Placebo (umeclidinium/vilanterol );   Drug: Placebo (QVA149)
2 Recruiting Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)
Condition: COPD
Interventions: Drug: BGF MDI 320/14.4/9.6 μg;   Drug: GFF MDI 14.4/9.6 μg;   Drug: BGF MDI 160/14.4/9.6 μg;   Drug: BFF MDI 320/9.6 μg
3 Recruiting Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History
Condition: Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Interventions: Drug: Benralizumab Arm A;   Drug: Benralizumab Arm B;   Drug: Placebo
4 Recruiting Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History
Condition: Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Interventions: Drug: Benralizumab Arm A;   Drug: Benralizumab Arm B;   Drug: Benralizumab Arm C;   Drug: Placebo
5 Recruiting Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Condition: COPD
Interventions: Drug: BGF MDI (PT010) 320/14.4/9.6 μg;   Drug: GFF MDI (PT003) 14.4/9.6 μg;   Drug: BFF MDI (PT009) 320/9.6 μg
6 Recruiting A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® (Kronos)
Condition: COPD
Interventions: Drug: BGF MDI 320/14.4/9.6 μg;   Drug: GFF MDI (PT003) 14.4/9.6 μg;   Drug: BFF MDI (PT009) 320/9.6 μg;   Drug: Symbicort® Turbuhaler® (TBH) Inhalation Powder
7 Recruiting Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD
Condition: COPD
Interventions: Drug: GFF MDI (PT003);   Drug: FF MDI (PT005);   Drug: GP MDI (PT001);   Drug: Placebo MDI
8 Recruiting AMPLIFY - D6571C00001 Duaklir USA Phase III Study
Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: Aclidinium bromide 400 μg/Formoterol Fumarate 12 μg (AB/FF 400/12 μg);   Drug: Aclidinium bromide 400 μg (AB 400 μg);   Drug: Formoterol fumarate 12 μg (FF 12 μg);   Drug: Placebo to AB/FF 400/12 μg, AB 400 μg and FF 12 μg;   Drug: Tiotropium 18 μg (TIO 18 μg);   Drug: Placebo to TIO 18 μg
9 Recruiting Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD
Condition: Chronic Obstructive Pulmonary Disorder
Interventions: Drug: BFF MDI 320/9.6 μg;   Drug: BFF MDI 160/9.6 μg;   Drug: FF MDI 9.6 μg;   Drug: BD MDI 320 μg;   Drug: Symbicort® TBH 400/12 μg BID
10 Recruiting Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb).
Condition: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Drug: Formoterol fumarate (6 μg);   Drug: Formoterol furmarate (20 μg);   Drug: Placebo for formoterol fumarate;   Drug: Formoterol fumarate (12 μg);   Drug: Formoterol fumarate (40 μg)
11 Not yet recruiting A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005 on COPD Exacerbations Over a 52-Week Period (Sophos)
Condition: Chronic Obstructive Pulmonary Disorder
Interventions: Drug: BFF MDI (PT009) 320/9.6 μg;   Drug: BFF MDI (PT009) 160/9.6 μg;   Drug: FF MDI (PT005) 9.6 μg
12 Recruiting A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251
Condition: Chronic Obstructive Pulmonary Disease, COPD
Interventions: Drug: QBW251;   Drug: Placebo
13 Unknown  Evaluation of FeNO During and Following Acute COPD Exacerbation
Condition: Chronic Obstructive Pulmonary Disease
Intervention: Device: NIOX MINO®
14 Not yet recruiting Safety of Anti-Depressant for Chronic Obstructive Pulmonary Disease (SAD-COPD)
Conditions: COPD;   Anxiety;   Depression;   Stress
Interventions: Drug: Sertraline;   Drug: Placebo
15 Not yet recruiting The Relationship Between GOLD Risk Group and Clinical Outcomes in a Community-based COPD Cohort
Conditions: Chronic Obstructive Pulmonary Disease (COPD);   Emphysema;   Chronic Bronchitis
Intervention:
16 Recruiting A Study to Evaluate Safety and Efficacy of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Condition: COPD, Chronic Obstructive Pulmonary Disease
Interventions: Drug: Lebrikizumab;   Drug: Placebo
17 Recruiting Imaging Regional Lung Defect Severity
Condition: COPD
Interventions: Drug: Perfluorinated Gas/Oxygen Mixture;   Other: High Resolution CT of the Chest
18 Recruiting Hyperpolarized 129Xe MRI for Imaging Pulmonary Function
Conditions: Asthma;   Chronic Obstructive Pulmonary Disease;   Interstitial Lung Disease;   Cystic Fibrosis;   Pulmonary Hypertension
Intervention: Drug: Xenon
19 Recruiting Evaluation of the Spiration® Valve System for Emphysema to Improve Lung Function
Condition: Emphysema
Interventions: Device: Spiration Valve System;   Other: Medical Management

Indicates status has not been verified in more than two years